National plaintiffs' law firm Berger Montague PCannounces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Company”) on behalf of investors who purchased MoonLake shares during the period ofMarch 10, 2024 through September 29, 2025 (the “Class Period”).
https://mma.prnewswire.com/media/232479/berger_montague.jpg
Investor Deadline: Investors who purchased MoonLakesecurities during the Class Period may, no later than December 15, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,CLICK HERE.
MoonLake, based in Zug, Switzerland, is a clinical-stage biotech firm focused on advancing next-generation immunotherapies.
According to the complaint, the Company repeatedly promoted its only drug candidate,sonelokimab (SLK), as a breakthrough treatment due to its Nanobody structure. The lawsuit alleges that the Companyfailed to disclose that SLK targets the same molecules as BIMZELX, an FDA-approved monoclonal antibody, and thus was not clinically superior to BIMZELX.
According to the suit, onSeptember 28, 2025, the Company disclosedPhase 3 trial results for SLK revealing that the drug failed to meet efficacy benchmarks. Analysts reportedly described the outcome as “disastrous,” andMoonLake's stock price declined by $55.75 per share – nearly 90% – in a single trading session.
If you are a MoonLake investor and would like to learn more about this action, CLICK HEREor please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.
About Berger MontagueBerger Montague is one of the nation's preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.
For more information or to discuss your rights, please contact:Andrew AbramowitzSenior CounselBerger Montague(215) 875-3015aabramowitz@bergermontague.com
Caitlin AdorniDirector of Portfolio & Institutional Client Monitoring ServicesBerger Montague(267) 764-4865cadorni@bergermontague.com
https://edge.prnewswire.com/c/img/favicon.png?sn=DC31705&sd=2025-11-24
View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025-302624150.html
SOURCE Berger Montague
https://rt.newswire.ca/rt.gif?NewsItemId=DC31705&Transmission_Id=202511240841PR_NEWS_USPR_____DC31705&DateId=20251124